/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Fate Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.06 0.0746(7.46%) FATE at 04 Dec 2025 04:31 PM Biotechnology
Lowest Today 1
Highest Today 1.085
Today’s Open 1
Prev. Close 1.005
52 Week High 2.93
52 Week Low 0.66
Day’s Range: Low 1 High 1.085
52-Week Range: Low 0.66 High 2.93
1 day return -
1 Week return -5.72
1 month return -10.46
3 month return +9.91
6 month return -24.64
1 year return -58.12
3 year return -94.75
5 year return -98.23
10 year return -

Institutional Holdings

Redmile Group, LLC 11.16

BlackRock Inc 9.37

Vanguard Group Inc 7.60

BB Biotech AG Ord 4.20

Citadel Advisors Llc 3.94

Johnson & Johnson 2.93

Vanguard Total Stock Mkt Idx Inv 2.59

iShares Russell 2000 ETF 2.25

Vanguard Strategic Equity Inv 2.20

Vestal Point Capital LP 2.18

Goldman Sachs Group Inc 2.18

Baker Bros Advisors LP 2.15

Dimensional Fund Advisors, Inc. 2.11

Morgan Stanley - Brokerage Accounts 2.11

Geode Capital Management, LLC 2.11

State Street Corp 1.93

Citigroup Inc 1.65

TANG CAPITAL MANAGEMENT LLC 1.62

Jacobs Levy Equity Management, Inc. 1.05

Fidelity Small Cap Index 0.95

Vanguard Institutional Extnd Mkt Idx Tr 0.84

UBS Group AG 0.83

BlackRock Advantage Small Cap Core Instl 0.82

iShares Russell 2000 Value ETF 0.82

Schonfeld Strategic Advisors LLC 0.81

Millennium Management LLC 0.76

AQR Capital Management LLC 0.73

Northern Trust Corp 0.73

DFA US Targeted Value I 0.61

Biotech Growth Ord 0.60

iShares Biotechnology ETF 0.55

Dimensional US Targeted Value ETF 0.51

Vanguard Russell 2000 ETF 0.46

Fidelity Extended Market Index 0.43

Bruce 0.37

Schwab US Small-Cap ETF™ 0.37

Vanguard Strategic Small-Cap Equity Inv 0.32

Multi-Manager Small Cap Eq Strat Inst 0.29

State St Russell Sm Cap® Indx SL Cl I 0.28

Vanguard Market Neutral I 0.27

Market Status

Strong Buy: 3

Buy: 2

Hold: 7

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 115.93 M

PB Ratio 0.5051

PE Ratio 0.0

Enterprise Value -17.94 M

Total Assets 440.69 M

Volume 1109589

Company Financials

Annual Revenue FY23:106213000 106.2M, FY22:96300000 96.3M, FY21:55846000 55.8M, FY20:31434000 31.4M, FY19:10680000 10.7M

Annual Profit FY23:null 0.0M, FY22:96300000 96.3M, FY21:55846000 55.8M, FY20:31434000 31.4M, FY19:10680000 10.7M

Annual Net worth FY23:-173169000 -173.2M, FY22:-255056000 -255.1M, FY21:-206301000 -206.3M, FY20:-170300000 -170.3M, FY19:-97708000 -97.7M

Quarterly Revenue Q3/2025:1741000 1.7M, Q2/2025:1907000 1.9M, Q1/2025:1629000 1.6M, Q3/2024:3074000 3.1M, Q2/2024:6772000 6.8M

Quarterly Profit Q3/2025:1741000 1.7M, Q2/2025:1907000 1.9M, Q1/2025:1629000 1.6M, Q3/2024:3074000 3.1M, Q2/2024:-27832000 -27.8M

Quarterly Net worth Q3/2025:-32250000 -32.3M, Q2/2025:-34070000 -34.1M, Q1/2025:-37621000 -37.6M, Q3/2024:-47678000 -47.7M, Q2/2024:-38427000 -38.4M

Fund house & investment objective

Company Information Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 181

Industry Biotechnology

CEO Dr. Bahram Valamehr M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow